This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Investors Heavily Search Medtronic PLC (MDT): Here is What You Need to Know
by Zacks Equity Research
Medtronic (MDT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Medtronic (MDT) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, Medtronic (MDT) stood at $83.52, denoting a +0.82% change from the preceding trading day.
Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exagen (XGN) delivered earnings and revenue surprises of 52.50% and 9.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's How Medtronic (MDT) Is Placed Ahead of Q4 Earnings
by Moumi Mondal
Medtronic's (MDT) rapid cadence of new product approvals is a strong foundation for future growth. However, the company also navigates some macroeconomic challenges.
Apyx Medical (APYX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of -22.22% and 6.27%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
National Vision (EYE) Q1 Earnings Top Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 7.14% and 2.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 12.25% and 0.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
The latest trading day saw Medtronic (MDT) settling at $81.76, representing a +0.09% change from its previous close.
Medtronic PLC (MDT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Medtronic (MDT). This makes it worthwhile to examine what the stock has in store.
Medtronic (MDT) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Medtronic (MDT) closed at $80.86 in the latest trading session, marking a +1.4% move from the prior day.
Medtronic PLC (MDT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Medtronic (MDT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Medtronic (MDT) Laps the Stock Market: Here's Why
by Zacks Equity Research
Medtronic (MDT) reachead $80.57 at the closing of the latest trading day, reflecting a +1.37% change compared to its last close.
Here's Why You Should Retain Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.
The Zacks Analyst Blog Highlights Mastercard, Netflix, Coca-Cola, Berkshire Hathaway and Medtronic
by Zacks Equity Research
Mastercard, Netflix, Coca-Cola, Berkshire Hathaway and Medtronic are included in this Analyst Blog.
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) concluded the recent trading session at $79.35, signifying a -1.1% move from its prior day's close.
Q1 Earnings Scorecard and Analyst Reports for Mastercard, Netflix & Coca-Cola
by Sheraz Mian
Today's Research Daily features a real-time update on the Q1 earnings season and new research reports Mastercard (MA), Netflix (NFLX) and Coke (KO) and others.
Medtronic PLC (MDT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Medtronic (MDT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Medtronic's (MDT) Sphere-360 PFA Study Outcome Favorable
by Zacks Equity Research
Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions.
Medtronic (MDT) Falls More Steeply Than Broader Market: What Investors Need to Know
by Zacks Equity Research
Medtronic (MDT) reachead $82.33 at the closing of the latest trading day, reflecting a -1.75% change compared to its last close.
Medtronic (MDT) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Medtronic (MDT) stood at $83.92, denoting a -1.27% change from the preceding trading day.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Medtronic's (MDT) Newest Evolut TAVR System Gets FDA Approval
by Zacks Equity Research
Medtronic (MDT) announces the FDA approval of the newest-generation Evolut TAVR system for the treatment of symptomatic severe aortic stenosis.
National Vision (EYE) Down 4.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott (ABT) Expands in Canada With First Eterna SCS Use
by Zacks Equity Research
Abbott's (ABT) Eterna SCS system reduces pain without causing discomfort. It leverages the BurstDR stimulation technology.
Medtronic (MDT) Down 2.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.